Big Pharma seeks long term remission x combining I/O therapyNovember 23, 2023 - Boehringer Ingleheim hopes to achieve its goal of boosting long-term remission rates among individuals with cancer, which currently only occur in 15% to 20% of patients, by combining complementary immuno-oncology platforms—such as T-cell engagers, oncolytic viruses and cancer vaccines—to expand the benefits of immunotherapy to more patients.
https://www.fiercebiotech.com/biotech/boehringer-builds-out-cancer-capabilities-acquires-swiss-biotech-deal-worth-508m